Literature DB >> 33370230

Heparin induced thrombocytopenia: position paper from the Italian Society on Thrombosis and Haemostasis (SISET).

Rossella Marcucci1, Martina Berteotti1, Anna M Gori1, Betti Giusti1, Angela A Rogolino1, Elena Sticchi1, Agatina Alessandrello Liotta1, Walter Ageno2, Erica De Candia3,4, Paolo Gresele5, Marina Marchetti6, Marco Marietta7, Armando Tripodi8.   

Abstract

Heparin induced thrombocytopenia (HIT) is a rare immune mediated adverse drug reaction occurring after exposure to heparin. It is a serious and potentially fatal condition, which may be associated with the development of arterial or venous thrombotic events. Although known for many years, HIT is still often misdiagnosed. Pre- test clinical probability, screening for anti-PF4/heparin antibodies and documentation of their platelet activating capacity are the cornerstones of diagnosis. However, both clinical algorithms and test modalities have limited predictive values and limited diffusion so that the diagnosis and management is challenging in the clinical practice. For this reason, there is an unmet need for novel rational non-anticoagulant therapies based on the pathogenesis of HIT.The present paper reports the position of the Italian Society on Haemostasis and Thrombosis (SISET) in order to increase awareness of HIT among clinicians and other health care professionals and to provide information on the most appropriate management.

Entities:  

Year:  2020        PMID: 33370230      PMCID: PMC7850929          DOI: 10.2450/2020.0248-20

Source DB:  PubMed          Journal:  Blood Transfus        ISSN: 1723-2007            Impact factor:   3.443


  67 in total

1.  Lower limb veins should be systematically explored in patients with isolated heparin-induced thrombocytopenia.

Authors:  B Tardy; B Tardy-Poncet; P Fournel; C Venet; R Jospe; A Dacosta
Journal:  Thromb Haemost       Date:  1999-09       Impact factor: 5.249

Review 2.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Lori-Ann Linkins; Antonio L Dans; Lisa K Moores; Robert Bona; Bruce L Davidson; Sam Schulman; Mark Crowther
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.

Authors:  B E Lewis; D E Wallis; S D Berkowitz; W H Matthai; J Fareed; J M Walenga; J Bartholomew; R Sham; R G Lerner; Z R Zeigler; P K Rustagi; I K Jang; S D Rifkin; J Moran; M J Hursting; J G Kelton
Journal:  Circulation       Date:  2001-04-10       Impact factor: 29.690

4.  A 14-year study of heparin-induced thrombocytopenia.

Authors:  T E Warkentin; J G Kelton
Journal:  Am J Med       Date:  1996-11       Impact factor: 4.965

Review 5.  The platelet serotonin-release assay.

Authors:  Theodore E Warkentin; Donald M Arnold; Ishac Nazi; John G Kelton
Journal:  Am J Hematol       Date:  2015-05-03       Impact factor: 10.047

6.  Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.

Authors:  Theodore E Warkentin; Richard J Cook; Victor J Marder; Jo-Ann I Sheppard; Jane C Moore; Bengt I Eriksson; Andreas Greinacher; John G Kelton
Journal:  Blood       Date:  2005-08-18       Impact factor: 22.113

7.  Assessment of a modified 4T scoring system for heparin-induced thrombocytopenia in critically ill patients.

Authors:  Mallory A Fiorenza; Erin N Frazee; Heather A Personett; Ross A Dierkhising; Garrett E Schramm
Journal:  J Crit Care       Date:  2013-12-30       Impact factor: 3.425

8.  A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia.

Authors:  A Greinacher; I Michels; V Kiefel; C Mueller-Eckhardt
Journal:  Thromb Haemost       Date:  1991-12-02       Impact factor: 5.249

9.  Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia.

Authors:  Bob Lobo; Christopher Finch; Amanda Howard; Sohail Minhas
Journal:  Thromb Haemost       Date:  2008-01       Impact factor: 5.249

10.  Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin.

Authors:  Sunil X Anand; Michael C Kim; Mazullah Kamran; Samin K Sharma; Annapoorna S Kini; Jawed Fareed; Debra A Hoppensteadt; Frank Carbon; Erdal Cavusoglu; David Varon; Juan F Viles-Gonzalez; Juan J Badimon; Jonathan D Marmur
Journal:  Am J Cardiol       Date:  2007-06-13       Impact factor: 2.778

View more
  4 in total

Review 1.  COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome.

Authors:  Massimo Franchini; Giancarlo Maria Liumbruno; Mario Pezzo
Journal:  Eur J Haematol       Date:  2021-06-09       Impact factor: 3.674

Review 2.  Interactions of adenoviruses with platelets and coagulation and the vaccine-induced immune thrombotic thrombocytopenia syndrome.

Authors:  Paolo Gresele; Stefania Momi; Rossella Marcucci; Francesco Ramundo; Valerio De Stefano; Armando Tripodi
Journal:  Haematologica       Date:  2021-12-01       Impact factor: 9.941

3.  Heparin-induced thrombocytopenia post-cardiovascular interventional therapy: a case report.

Authors:  Lishui Shen; Xiaohua Liu; Lian Chen; Xiaofei Gao; Yizhou Xu
Journal:  BMC Cardiovasc Disord       Date:  2022-08-03       Impact factor: 2.174

4.  Vaccine-induced thrombotic thrombocytopenia: the elusive link between thrombosis and adenovirus-based SARS-CoV-2 vaccines.

Authors:  Rossella Marcucci; Marco Marietta
Journal:  Intern Emerg Med       Date:  2021-06-30       Impact factor: 3.397

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.